Horizon Sees Blockbuster Future For Tepezza After US Approval
First Treatment For Thyroid Eye Condition
Once a pariah because of its price gouging, the new approval represents a change of tack from Horizon.
You may also be interested in...
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
“Growth gaps” were the driver for a record-breaking M&A year – but CEOs must remain disciplined when pursuing opportunities, or pay the price down the line.